ATG7 and cancer: In addition, in terms of cancer therapy in advanced PDAC, this raises the possibility that lower doses of ATG7-specific inhibitors, that reduce ATG7 function, but do not completely ablate autophagy, may result in therapeutics that could repress metastasis without affecting the beneficial effects of autophagy in normal tissue.